Astellas Pharma Inc. will present 21 abstracts from its oncology portfolio at the European Society for Medical Oncology Congress 2026, taking place from 23 to 27 October in Madrid, Spain. The presentations cover prostate, urothelial, gastric and gastroesophageal junction (GEJ), lung and pancreatic cancers, and reflect the company’s aim of raising standards of care in cancers with significant unmet need.
Moitreyee Chatterjee-Kishore, Ph.D., MBA, executive vice president and head of oncology development at Astellas, said standards of care do not change by accident. She said the data at ESMO 2026 show how a deep understanding of disease biology and differentiated treatment approaches is moving care forward in bladder, gastric and prostate cancers, including through PADCEV™ (enfortumab vedotin) plus pembrolizumab, VYLOY™ (zolbetuximab) and XTANDI™ (enzalutamide). She added that Astellas is building on this knowledge to develop the next generation of options for cancers where needs remain unmet, and looks forward to discussing the work at the congress.
The enfortumab vedotin presentations include the longest follow up reported so far in locally advanced or metastatic urothelial cancer, together with analyses across patient subgroups and treatment settings. Trials in progress exploring bladder preservation in muscle invasive bladder cancer will also be shown. The zolbetuximab presentations look at CLDN18.2 testing, patient identification and real world use, adding to the evidence for CLDN18.2 guided treatment decisions in gastric and GEJ cancers.
Pipeline presentations focus on trials in progress. They include Phase 3 trials of setidegrasib in KRAS G12D mutated pancreatic and non small cell lung cancers, a Phase 1 trial of ASP5834 in solid tumours with KRAS mutations or amplifications, and a Phase 1b/2 trial of ASP546C in solid tumours expressing CLDN18.2. Astellas says these studies show its continued investment in new approaches to cancers where progress has been limited.
Astellas presentations at ESMO 2026
Enfortumab vedotin
| Presentation | Lead author | Details |
|---|---|---|
| EV-103 DE/Cohort A and Cohort K final analysis: enfortumab vedotin with or without pembrolizumab as first-line treatment for cisplatin-ineligible locally advanced or metastatic urothelial carcinoma, long-term follow-up | J. P. Maroto Rey | Rapid oral, abstract 4740RO, Saturday 24 October, 10:15 to 11:45 |
| EV-302 comorbidities (DCO3): updated exploratory analysis in older patients and those with comorbidities | S. S. Sridhar | Poster, abstract 4761P, Friday 23 October, 15:15 to 16:00 |
| EV-302 clinical subgroups (DCO3): exploratory analyses based on disease-related characteristics | J. Bedke | Poster, abstract 4760P, Friday 23 October, 15:15 to 16:00 |
| EVOLVE 3: real-world treatment patterns in locally advanced and metastatic urothelial cancer in France | F. Joly | ePoster |
| EV-303/KN-905 ITT3: perioperative pembrolizumab or enfortumab vedotin plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer, ad hoc analysis from KEYNOTE-905 | A. Ullén | Proffered paper session, abstract 4733O, Friday 23 October, 13:30 to 15:00 |
| EV-304/KN-B15 ctDNA: ctDNA analysis of the phase 3 KEYNOTE-B15 trial in cisplatin-eligible muscle-invasive bladder cancer | J. Chatzkel | Proffered paper session, abstract 4734O, Friday 23 October, 13:30 to 15:00 |
| EV-304/KN-B15 ePRO: health-related quality of life with neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer | A. Gómez De Liaño | Rapid oral, abstract 4738RO, Saturday 24 October, 10:15 to 11:45 |
| EV-209 TiP: phase 2 study of enfortumab vedotin plus pembrolizumab for bladder preservation in muscle-invasive bladder cancer eligible for radical cystectomy | Thomas Powles | Poster, abstract 4769TiP, Friday 23 October, 15:15 to 16:00 |
| EV-309 TiP: phase 3 study of enfortumab vedotin plus pembrolizumab for bladder preservation in muscle-invasive bladder cancer | Matthew D. Galsky | Poster, abstract 4770TiP, Friday 23 October, 15:15 to 16:00 |
Enzalutamide
| Presentation | Lead author | Details |
|---|---|---|
| Adelpi REALIZE: European real-world evidence on risk stratification, PSMA PET use and physician practices in high-risk biochemically recurrent hormone sensitive prostate cancer | A. Merseburger | ePoster, abstract 2063eP |
| AMNOG NMA in mHSPC: network meta-analysis on the safety of androgen receptor pathway inhibitors from German AMNOG dossiers | C. Ohlmann | Poster, abstract 2295P, Friday 23 October, 15:15 to 16:00 |
| CASPER: Canadian real-world outcomes of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer | B. Shayegan | ePoster, abstract 2329eP |
| ARCHES/ARANOTE indirect safety comparison of enzalutamide and darolutamide with ADT in metastatic hormone-sensitive prostate cancer | S. Shariat | Poster, abstract 2294P, Friday 23 October, 15:15 to 16:00 |
| EMBARK deep PSA response by prior definitive treatment in high-risk biochemically recurrent prostate cancer, post hoc analysis | S. Freedland | Poster, abstract 2293P, Friday 23 October, 15:15 to 16:00 |
Zolbetuximab
| Presentation | Lead author | Details |
|---|---|---|
| SPOTLIGHT ctDNA: ctDNA assessment in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma | K. Shitara | Poster, abstract 2882P, Sunday 25 October, 12:00 to 12:45 |
| Canadian PSP: real-world use of zolbetuximab plus chemotherapy in a Canadian patient support program | H. Karachiwala | Poster, abstract 2941P, Sunday 25 October, 12:00 to 12:45 |
Pipeline
| Presentation | Lead author | Details |
|---|---|---|
| Phase 3 PDAC TiP: setidegrasib plus mFOLFIRINOX or NALIRIFOX as first-line treatment for metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutations | T. Macarulla | Poster, abstract 3190TiP, Sunday 25 October, 12:00 to 12:45 |
| Phase 3 NSCLC TiP: setidegrasib versus docetaxel in KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer after platinum chemotherapy and checkpoint inhibitor therapy | F. Skoulidis | ePoster, abstract 2871eTiP |
| Phase 1b/2 TiP: ASP546C, a Claudin 18.2-targeting antibody-drug conjugate, in Claudin 18.2-expressing solid tumours | T. Macarulla | ePoster, abstract 1133eTiP |
| FiH TiP: phase 1 study of ASP5834 in solid tumours with KRAS mutations or amplifications | S. Sen | ePoster, abstract 1145eTiP |
| Combination clinical data: phase 1/2 study of ASP1570 in locally advanced or metastatic microsatellite-stable colorectal cancer | V. Boni | ePoster, abstract 1090eP |
